XILOClinical Trials•globenewswire•
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
Sentiment:Positive (70)
Summary
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire